Key Points:
- Natural killer (NK) cells represent innate immune cells with potent antitumor activity.
- Glycostem Therapeutics has established an innovative production process that yields high numbers of allogeneic NK cells with potent activity towards both hematologic and solid malignancies which can be used “off-the-shelf”.
- In a first-in-human phase I study in elderly patients with acute myeloid leukemia, these NK cells were well tolerated, had a favorable toxicity profile and were associated with promising efficacy.
- The possibility to genetically engineer the NK cells with chimeric antigen receptors or T cell receptors offers additional opportunities in immuno-oncology.
